Skip to content

Capricor Therapeutics CAPR Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.29M+394%
Vericel logo
VericelVCEL
-$21K-425%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$169K-2,917%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$8.8M-291%
Pfizer logo
PfizerPFE
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$1.71B+303%
Enterprise value$1.62B+308%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Capricor Therapeutics's other noncash income (expense)?
Capricor Therapeutics (CAPR) reported other noncash income (expense) of $6.59K in Q1 2026.
What does other noncash income (expense) mean?
This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.